Genentech, a member of the Roche Group, announced today (May 22, 2017) that the U.S. Food and Drug Administration (FDA) has approved Actemra® (tocilizumab) subcutaneous injection for the treatment of more »
The Vasculitis Foundation is pleased to present the 2017 Vasculitis Update CME Course for health care professionals in partnership with Northwestern Division of Rheumatology on Saturday, June 24, 2017 from 7:45 more »
The Vasculitis Foundation (VF) announces the winner of its 2017 Recognizing Excellence in Diagnostics (RED) Award. The V-RED Award is presented annually to a medical professional who made a quick diagnosis of more »
The Vasculitis Foundation is pleased to announce its Dream Big! campaign. The aim of this year-long campaign is to fast track the advances about which every person impacted by vasculitis is dreaming: faster diagnosis; better, less invasive treatments; and, ultimately, a cure for all forms of the disease. Click here to learn more!